Evidence map›Paper›PMID 32700810›Full record

ArticleInternational journal of cancer2021

Comprehensive genomic landscape and precision therapeutic approach in biliary tract cancers.

Ryosuke Okamura, Razelle Kurzrock, Robert J Mallory, Paul T Fanta, Adam M Burgoyne, Bryan M Clary, Shumei Kato, Jason K Sicklick

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed
7.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 72 citations in OpenAlex.

  1. Trial
  2. Existing challenges in the management of cholangiocarcinoma in Spain.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Biliary tract cancers: advances in diagnostic and management.Exploration of targeted anti-tumor therapy · 2025
    Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Ryosuke OkamuraCenter for Personalized Cancer Therapy, UC San Diego Moores Cancer Center, La Jolla, California, USA.ORCID 0000-0001-7352-8621
Razelle KurzrockCenter for Personalized Cancer Therapy, UC San Diego Moores Cancer Center, La Jolla, California, USA.ORCID 0000-0003-4110-1214
Robert J MalloryDivision of Surgical Oncology, Department of Surgery, UC San Diego Moores Cancer Center, La Jolla, California, USA.
Paul T FantaDivision of Hematology-Oncology, UC San Diego Moores Cancer Center, La Jolla, California, USA.
Adam M BurgoyneDivision of Hematology-Oncology, UC San Diego Moores Cancer Center, La Jolla, California, USA.
Bryan M ClaryDivision of Surgical Oncology, Department of Surgery, UC San Diego Moores Cancer Center, La Jolla, California, USA.
Shumei KatoCenter for Personalized Cancer Therapy, UC San Diego Moores Cancer Center, La Jolla, California, USA.ORCID 0000-0003-1193-1815
Jason K SicklickCenter for Personalized Cancer Therapy, UC San Diego Moores Cancer Center, La Jolla, California, USA.ORCID 0000-0003-4403-0271
UC San Diego Health System · USUniversity of California San Diego · US

Funding

VIRAL MALIGNANCYP30CA023100 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Jesse Nodora · 1985 to 2026
$124.9M
Targeting Drug-Resistant Cancer Stem Cell Niches of Gastrointestinal Stromal TumorR01CA226803 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SICKLICK, JASON KEITH · 2019 to 2023
$2.1M
Investigation of DNA Damaging Agents in GIST with Metabolic DysfunctionR01FD006334 · FDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SICKLICK, JASON KEITH · 2019 to 2021
$1.5M
FDA HHS R01 FD006334NCI NIH HHS P30 CA023100NCI NIH HHS R01 CA226803
6 · The paper itself

Abstract

Biliary tract cancers have dismal prognoses even when cytotoxic chemotherapy is administered. There is an unmet need to develop precision treatment approaches using comprehensive genomic profiling. A total of 121 patients with biliary tract cancers were analyzed for circulating-tumor DNA (ctDNA) and/or tissue-based tumor DNA (tissue-DNA) using clinical-grade next-generation sequencing: 71 patients (59%) had ctDNA; 90 (74%), tissue-DNA; and 40 (33%), both. Efficacy of targeted therapeutic approaches was assessed based upon ctDNA and tissue-DNA. At least one characterized alteration was detected in 76% of patients (54/71) for ctDNA [median, 2 (range, 0-9)] and 100% (90/90) for tissue-DNA [median, 4 (range, 1-9)]. Most common alterations occurred in TP53 (38%), KRAS (28%), and PIK3CA (14%) for ctDNA vs TP53 (44%), CDKN2A/B (33%) and KRAS (29%) for tissue-DNA. In 40 patients who had both ctDNA and tissue-DNA sequencing, overall concordance was higher between ctDNA and metastatic site tissue-DNA than between ctDNA and primary tumor DNA (78% vs 65% for TP53, 100% vs 74% for KRAS and 100% vs 87% for PIK3CA [But not statistical significance]). Among 80 patients who received systemic treatment, the molecularly matched therapeutic regimens based on genomic profiling showed a significantly longer progression-free survival (hazard ratio [95%confidence interval], 0.60 [0.37-0.99]. P = .047 [multivariate]) and higher disease control rate (61% vs 35%, P = .04) than unmatched regimens. Evaluation of ctDNA and tissue-DNA is feasible in biliary tract cancers.

Indexed as

AdultAgedAged, 80 and overAntineoplastic AgentsBiliary Tract NeoplasmsCirculating Tumor DNAClass I Phosphatidylinositol 3-KinasesCyclin-Dependent Kinase Inhibitor p15Cyclin-Dependent Kinase Inhibitor p16DNA, NeoplasmFeasibility StudiesFemaleHigh-Throughput Nucleotide SequencingHumansMaleMiddle AgedAntineoplastic AgentsCDKN2A protein, humanCDKN2B protein, humanCirculating Tumor DNAClass I Phosphatidylinositol 3-KinasesCyclin-Dependent Kinase Inhibitor p15Cyclin-Dependent Kinase Inhibitor p16DNA, NeoplasmKRAS protein, humanPIK3CA protein, humanProto-Oncogene Proteins p21(ras)TP53 protein, humanTumor Suppressor Protein p53biliary tract cancersbiomarkercholangiocarcinomacirculating tumor DNAliquid biopsymolecular profilingpersonalized cancer therapy

Identifiers

PMID32700810
PMCPMC7739197
OpenAlexW3021195724

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.